COVID-19 convalescent plasma composition and immunological effects in severe patients

Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the composition and mechanism of action are not fully known. Therefore, we undertook a two-phase controlled study in which, first the immunological and metabolomic status of recovered and severe patients were evaluated. Secon...

Full description

Saved in:
Bibliographic Details
Published in:Journal of autoimmunity 2021-03, Vol.118, p.102598-102598, Article 102598
Main Authors: Acosta-Ampudia, Yeny, Monsalve, Diana M., Rojas, Manuel, Rodríguez, Yhojan, Gallo, Juan Esteban, Salazar-Uribe, Juan Carlos, Santander, María José, Cala, Mónica P., Zapata, Wildeman, Zapata, María Isabel, Manrique, Rubén, Pardo-Oviedo, Juan Mauricio, Camacho, Bernardo, Ramírez-Santana, Carolina, Anaya, Juan-Manuel
Format: Article
Language:English
Subjects:
Adult
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Autoantibodies
B-Lymphocytes - metabolism
CD4-Positive T-Lymphocytes - metabolism
CD8-Positive T-Lymphocytes - metabolism
Convalescent plasma
COVID-19
COVID-19 - blood
COVID-19 - therapy
COVID-19 Serotherapy
Cytokines
Female
Humans
Immunization, Passive
Interleukin-10 - blood
Interleukin-6 - blood
Male
Memory cells
Metabolomic profile
Middle Aged
SARS-CoV-2
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the composition and mechanism of action are not fully known. Therefore, we undertook a two-phase controlled study in which, first the immunological and metabolomic status of recovered and severe patients were evaluated. Secondly, the 28-day effect of CP on the immune response in severe patients was assessed. Nineteen recovered COVID-19 patients, 18 hospitalized patients with severe disease, and 16 pre-pandemic controls were included. Patients with severe disease were treated with CP transfusion and standard therapy (i.e., plasma recipients, n = 9) or standard therapy alone (n = 9). Clinical and biological assessments were done on day 0 and during follow-up on days 4, 7, 14, and 28. Clinical parameters, viral load, total immunoglobulin (Ig) G and IgA anti-S1-SARS-CoV-2 antibodies, neutralizing antibodies (NAbs), autoantibodies, cytokines, T and B cells, and metabolomic and lipidomic profiles were examined. Total IgG and IgA anti-S1-SARS-CoV-2 antibodies were key factors for CP selection and correlated with NAbs. In severe COVID-19 patients, mostly interleukin (IL)-6 (P = 
ISSN:0896-8411
1095-9157
1095-9157
DOI:10.1016/j.jaut.2021.102598